Evidence map›Paper›PMID 37898724›Full record

ArticleBritish journal of cancer2023

Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy.

Xiaoshuang Feng, Yiwen Zhang, J Bailey Vaselkiv, Ruifeng Li, Paul L Nguyen, Kathryn L Penney, Edward L Giovannucci, Lorelei A Mucci, Konrad H Stopsack

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Xiaoshuang Feng *Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Yiwen Zhang *Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0002-1193-2263
J Bailey VaselkivDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Ruifeng LiDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Paul L NguyenDepartment of Radiation Oncology, Brigham and Women's Hospital/Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Kathryn L PenneyDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Edward L GiovannucciDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.ORCID 0000-0002-6123-0219
Lorelei A MucciDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA.
Konrad H StopsackDepartment of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA. kstopsack@mgh.harvard.edu.ORCID 0000-0002-0722-1311
Harvard University · USBrigham and Women's Hospital · US

Funding

Cancer Epidemiology Cohort in Male Health ProfessionalsU01CA167552 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Lorelei Mucci, Walter C. Willett · 2017 to 2026
$17.0M
Impact of screening and diagnostic intensity on the study of prostate cancer epidemiologyR03CA226942 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI GIOVANNUCCI, EDWARD · 2019 to 2020
$160k
NCI NIH HHS R03 CA226942NCI NIH HHS U01 CA167552World Health Organization 001
6 · The paper itself

Abstract

backgroundPreviously suggested modifiable risk factors for prostate cancer could have resulted from detection bias because diagnosis requires a biopsy. We investigated modifiable risk factors for a subsequent cancer diagnosis among men with an initially negative prostate biopsy.

methodsIn total, 10,396 participants of the Health Professionals Follow-up Study with an initial negative prostate biopsy after 1994 were followed for incident prostate cancer until 2017. Potential risk factors were based on previous studies in the general population. Outcomes included localised, advanced, and lethal prostate cancer.

resultsWith 1851 prostate cancer cases (168 lethal) diagnosed over 23 years of follow-up, the 20-year risk of any prostate cancer diagnosis was 18.5% (95% CI: 17.7-19.3). Higher BMI and lower alcohol intake tended to be associated with lower rates of localised disease. Coffee, lycopene intake and statin use tended to be associated with lower rates of lethal prostate cancer. Results for other risk factors were less precise but compatible with and of similar direction as for men in the overall cohort.

conclusionsRisk factors for future prostate cancer among men with a negative biopsy were generally consistent with those for the general population, supporting their validity given reduced detection bias, and could be actionable, if confirmed.

Indexed as

ProstateProstatic NeoplasmsBiopsyFollow-Up StudiesHumansMaleRisk Factors

Identifiers

PMID37898724
PMCPMC10703766
OpenAlexW4388001299

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.